Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IND Sponsors Should Not Contact FDA Reviewers Directly, Draft Guidance Asserts

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry has pressed for more latitude on communications with agency, but FDA emphasizes that review division regulatory project managers should be primary contact.

You may also be interested in...



US FDA To Sponsors: Tell Us More About Your Drug Development Before We Meet

Requests for meetings with FDA staff about products in development should include pertinent details about pediatric study plans, human factors engineering plans and combination product information; new guidance documents on formal meetings under PDUFA VI and communications with IND sponsors operationalize user fee program commitments and will promote earlier, more thorough engagement, agency says.

PDUFA VI: BIO Survey Finds FDA Communication Problems

Data may help industry stake out its negotiating position as formal talks near for user fee reauthorization.

What Might FDA Do Post Roe? Eliminate Mifepristone REMS

Attorneys say the biggest step FDA could take to expand access to abortion medication would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel